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O

n December 12-13, FDLI hosted the annual Enforcement, Litigation & Compliance conference in Washington, DC. The two-day conference was packed with
extremely informative topics, and included an astounding
number of high-level government officials from the Food
and Drug Administration (FDA), the Department of Health
and Human Services (HHS) Office of the Inspector General
(OIG), the Department of Justice (DOJ), and several other
related offices.
Below is a summary of some of the panels, quotes from participants, and some overall analysis and commentary. It should
be noted that all participants from the government spoke on
their own behalf and were not speaking on behalf of their
respective agencies.

New Faces of Enforcement
he irst panel of the conference included some of the top
oicials in food and drug law and healthcare enforcement. he
panel, moderated by Eugene M. hirolf, former Director of the
DOJ Consumer Protection Branch, consisted of:
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•

Michael S. Blume, Director, Consumer Protection
Branch, U.S. Department of Justice

•

Gregory Demske, Chief Counsel to the Inspector
General, HHS-OIG

•

Joseph Rannazzisi, Deputy Assistant Administrator,
Oice of Diversion Control, U.S. Drug Enforcement
Administration (DEA)

•

John Roth, Director, Oice of Criminal
Investigation, FDA
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Greg Demske spoke irst, noting that although OIG will not
make any major changes to its enforcement priorities, there will be
diferent approaches to the way OIG handles cases. He mentioned
the need for change given the continuously large settlements,
questioning whether OIG and healthcare law enforcement is doing
enough. Demske assured the audience that OIG will continue to
work closely with industry to engage in a productive dialogue,
promote voluntary compliance, and to identify best practices for
compliance and ighting healthcare fraud and waste. He noted that
OIG will hopefully continue to engage industry like it has in the
past year, with more industry roundtables.
Demske did emphasize that OIG will “focus on individuals
and the decisions they are making,” in reference to DOJ’s more
recent focus on the Park doctrine, and OIG’s use of convictions
under that doctrine to exclude individuals. In making this
remark, he explained to the audience OIG’s exclusion authority,
the diferences between mandatory and permissive exclusion,
and discussed the Synthes and Purdue Pharma cases. Demske
also discussed the use of corporate integrity agreements (CIAs),
and how OIG decides whether to waive exclusion in order for
the company or entity to enter into a CIA. In referencing the
Purdue case, he noted how the D.C. Circuit court denied the
executives request for a hearing en banc (all judges of the court),
leaving executives with only the option of petitioning the Supreme Court for a writ of certiorari.
Finally, Demske discussed GlaxoSmithKline’s (GSK) recent
CIA with OIG, and the new provisions addressing the “Patient
First Program” and the “claw back” provisions for executive
compensation and bonuses.
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Michael S. Blume, Director, Consumer Protection Branch, U.S. Department of Justice, engaged the audience during his
address during the “New Faces of Enforcement” keynote.

Joseph Rannazzisi gave the next presentation, which focused

centers at FDA (e.g. CDER, CDRH) to get information

primarily on the tremendous public health concern our coun-

about where its enforcement priorities should be and

try is facing regarding abuse of opioids and other pain killers.
His animated presentation gave useful data and insight into the

where to investigate.
OCI handles cases involving counterfeit pharmaceuticals

tremendous extent of this problem and the harmful efects it is

(such as the recent Avastin case) and is also responsible for

having on our healthcare system as well as the costs. He gave an

investigating companies that may have committed clinical trial

overview of how DEA operates and its legal authority and ju-

fraud or made misrepresentations to FDA in their product ap-

risdiction under the Controlled Substances Act (CSA), and the

plication or required post-market reporting.

agency’s work with DOJ, FBI, and other federal healthcare law

Finally, Michael Blume discussed DOJ’s enforcement priori-

enforcement. He also discussed several cases, including one in

ties and how his oice handles cases. he Consumer Protection

which individuals were driving all the way from Massachusetts

Branch (CPB) is involved in all cases involving the FDCA and is

to Florida to get opioids.
Next, John Roth gave a presentation on FDA’s Office of

largely involved in many of the of-label promotion cases. Blume
noted that his oice is working in an environment of limited re-

Criminal Investigations (OCI). He gave a broad overview

sources, but nevertheless, uses data from various sources to help

of OCI’s mission, explained the nature of their work and

determine a proactive approach at pursuing cases. He said that

gave some examples of recent actions and cases. OCI

CPB is reaching out more aggressively to stakeholders and con-

mainly deals with injunctions, seizures and criminal

sumers in the industry, and is looking for cases that will change

enforcement of the Food, Drug & Cosmetic Act. OCI

the behavior of industry and have a larger impact on stakehold-

works with DOJ and other law enforcement to protect

ers, rather than just looking for big money settlements.

the public health and has highly trained investigators
that help carry out its work. OCI works closely with the
FDLI

Blume noted that his oice is being more transparent about
the facts of each case and the unlawful conduct that occurred so
January/February 2013
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the oice can send a message or
signal to stakeholders. In other
words, those facts and unlawful
conduct made public are a warning for companies to know that
they may get a knock on their
door if similar conduct occurs
in their business. Finally, Blume
noted CPB’s look into requiring
more compliance, despite OIG’s
role. He noted that his oice is
working with OIG and having
a discussion about ways to hold
companies responsible and the
right factual circumstances to
include enhanced penalties such
as required compliance that
is separate and additional to a
Mary A. Malarkey, Director, Ofice of Compliance and Biologics Quality, presented the
notable compliance work done by CBER in 2012.
CIA. Blume also noted that CPB
is seeing more medical device
cases involving defects or failure
to make required reporting, and
that this may be a growth area for the oice.

Compliance Central with FDA Center
Compliance Directors
his panel included the top oicials from all of FDA’s
Centers, including drugs, devices, biologics, foods, tobacco
and veterinary medicine. A signiicant amount of discussion from CDER focused on the new authorities under the
Food and Drug Administration Safety and Innovation Act
(FDASIA) regarding the drug supply chain. Douglas Stearn,
Deputy Director for Policy and Analysis, Oice of Compliance,
CDER, discussed the new oice in CDER that deals with drug
supply chain issues and counterfeiting as well as a new trend
in enforcement letters from FDA dealing with current good
manufacturing practices (cGMP) violations.
In response to a question about why FDA sent a cGMP
warning letter directly to a CEO or senior level oicials, Stearn
noted that the agency did so because quality control is a corporate commitment that FDA believes needs to be taken seriously
by senior management. He noted how quality control is now an
aspect of the company that is integrated, so it is important that
someone is held accountable.
he CDRH presentation also included a very interesting discussion of new programs the center is working on such as the
Single Audit Program and the Case for Quality Initiative.
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Brien T. O’Connor, Partner, Ropes & Gray LLP, discussed
considerations when deciding whether to negotiate a preiling resolution or to contest the government’s case in a trial.

Advanced Applications Panel
his panel consisted of Jill Furman (Deputy Director, Consumer Protection Branch (CPB), U.S. Department of Justice),
Christopher B. Mead (Attorney, London & Mead) and Brien T.
O’Connor (Partner, Ropes & Gray LLP). he panel traced some
of the steps the government goes through in deciding whether
to bring a case for an alleged FDCA violation. First, Ms. Furman noted that a large number of cases that CPB handles come
from qui tam relators or “whistleblowers.” Under the Qui Tam
www.fdli.org
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The Second Circuit decision vacated the conviction of Alfred Caronia for promoting a drug for off-label use on First Amendment
grounds. During the “Hot Topics in Enforcement: 2012 Review, 2013 Preview”, John Fleder lead a discussion on what this
means for the food and drug law community.

statute, the government must review each qui tam; however,
the discretion and process for such review varies by oice and
agency, thus there is not necessarily a statutory outline for what
factors and considerations the government will look at.
Instead, Furman noted that CPB looks at whether there have
been any regulatory actions against the alleged company or products by FDA or a speciic center; whether there is a public health
concern; whether there have been a large number of warning
letters; and several other factors. She also noted the importance
of a company’s initial response to an inquiry, including, where
the response came from, the perspective of ixing the problem,
and who was hurt. In general, she noted that the focus of CPB is
the harm to patients/consumers caused by the product. She also
discussed where the product its in at the company, the regulatory
and/or enforcement history of the company, any communications
between the agency and the company about the product, and the
pervasiveness of the conduct or actions.
Another important factor Furman mentioned was how
the alleged conduct afects the regulatory approval process or
oversight of the agency. Consequently, she noted that her oice
decides on pursuing cases, issuing subpoenas, looking at documents, etc., when the basic fact and factors noted above show
that a likely result will be restitution that is worth the resources
FDLI

put into it. Nevertheless, she noted that cases brought to CPB
require a lot of resources, sometimes 2-3 agents and 2-3 lawyers,
which can be full-time and has consequences when those government actors are unable to pursue other cases or work.
here was also a brief discussion about when DOJ Criminal
decides to get involved in FDCA violation cases. It was noted
that DOJ Criminal, CPB, FDA, and other enforcement agencies
work together to share information about a particular case and
based on that work make a decision whether to pursue criminal
charges. his raised concerns from some criminal defense attorneys because many companies and executives have a distrust
about DOJ coming back ater the civil case is resolved bringing
criminal charges. hey expressed their preference of resolving
cases “globally,” to avoid this problem.
Chris Mead, the attorney who represented Mark Hermelin,
the former KV Pharmaceutical CEO who was excluded from
federal health programs last year, discussed several aspects of
the case and made a recommendation based on his experience.
He said that CEOs should not be more involved in clinical and
quality decisions then they need to be. In the case of Hermelin,
he was heavily involved in the decision making that led to the
company using improper machines that resulted in the creation
of adulterated products. his involvement was the primary
January/February 2013
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Howard R. Sklamberg, Deputy Associate Commissioner for Regulatory Affairs, ORA, FDA, outlined challenges faced by FDA in
protecting public health while maintaining international and federal-state relations.

conduct that led to his convictions and eventual exclusions. Be-

denies a company’s claim about another use or the company

cause it appeared based on his role as CEO that these decisions

submits additional data about pursuing an of-label indica-

were made out of greed and a total disregard for public health

tion, with which FDA disputes, and then a company goes and

and patient safety, Mead said that other executives should take

promotes it of-label—Caronia makes it uncertain what the out-

a hands-of approach in manufacturing and clinical decisions.

come would be if FDA prosecuted such conduct. It was noted,

Doing so may ensure that the company’s decisions are being

however, that under such facts, a company may be misleading

made in an unbiased and impartial way that prioritizes public

or making false statements about its product given FDA’s rejec-

health and patient safety over proits.

tion or dispute regarding the of-label use.

Hot Topics and U.S. v. Caronia
he last panel of the irst day included a healthy discussion

negotiation of damages with the government, particularly when

of the recent 2nd Circuit Opinion in U.S. v. Caronia. he various

false claims are involved, may be afected. For example, in calculat-

panel members discussed their viewpoints and made predic-

ing damages and false claims, the government typically tries to

tions about the future of the case and its potential implications.

quantify the amount of prescriptions or the “market” for of-label

Several interesting points were made.

use. In making this calculation, they may consider a certain

First, one commentator noted that for many of the compa-
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he panel also noted that given this opinion, the calculation and

percentage of doctors who were prescribing of-label without the

nies that are involved in of-label promotion cases, the company

efect of detailing or sales reps. Now with Caronia, as long as a sales

usually communicated with FDA about pursuing an of-label

rep’s speech is truthful and non-misleading, then the claims being

indication. Consequently, the panel noted that if FDA expressly

submitted for them may no longer be “false.”
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